Sanofi


Factoring in API business’ spinoff + a strong Q1

18/05/22 -"We have updated our model to incorporate the impact of the spin-off of the API (active pharmaceutical ingredient) business, which had listed separately as EUROAPI – now part of the NAV as an equity ..."

Pages
72
Language
English
Published on
18/05/22
You may also be interested by these reports :
20/08/26
Moderna’s late-stage skin cancer vaccine success nearly tripled its share price yesterday and opened a new realm within cancer treatment. Other ...

14/08/26
Since we last teased this name on 3 January 2025 — arguing there was little incremental upside left after a strong run and a post-merger valuation ...

04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...

07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO